Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma

Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions

(2021) Abolfazl Maghrouni et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma

(2021) Dorothee Hölzl et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pituitary-Tumor Endocrinopathies

(2020) Shlomo Melmed   NEW ENGLAND JOURNAL OF MEDICINE

Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview

(2020) Subha Mondal et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Individual Treatment Decisions for Central Neurocytoma

(2020) Song Han et al.   Frontiers in Neurology

Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors

(2019) Mizuto Sato et al.   Journal of Clinical Medicine

Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab

(2019) Mario Caccese et al.   ANTI-CANCER DRUGS

Targeting PD-L1 initiates effective anti-tumor immunity in a murine model of Cushing's Disease

(2019) Hanna R Kemeny et al.   CLINICAL CANCER RESEARCH

Pituitary Apoplexy

(2019) Garni Barkhoudarian et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours

(2019) Pedro Marques et al.   Acta Neuropathologica Communications

The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy

(2018) Peng-fei Wang et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions

(2018) Luis V. Syro et al.   Frontiers in Endocrinology

PD-1 ( PDCD1 ) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase ( IDH ) Mutations

(2018) Lea Kristin Röver et al.   EBioMedicine

The Relationship Between Phospho-p38, Matrix Metalloproteinase 9, and Major Histocompatibility Complex Class I Chain-Related Molecule A Expression in Pituitary Adenomas Demonstrates a New Mechanism of Pituitary Adenoma Immune Escape

(2018) Xinyu Han et al.   World Neurosurgery

Diagnosis and Treatment of Pituitary Adenomas

(2017) Mark E. Molitch   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification

(2017) Gérald Raverot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas

(2017) Alexander S. G. Micko et al.   Pituitary

O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis

(2017) Congxin Dai et al.   Oncotarget

Diverse macrophages polarization in tumor microenvironment

(2016) Inmoo Rhee   ARCHIVES OF PHARMACAL RESEARCH

The Multifaceted Role of Perivascular Macrophages in Tumors

(2016) Claire E. Lewis et al.   CANCER CELL

How effective is temozolomide for treating pituitary tumours and when should it be used?

(2016) Carmel Halevy et al.   Pituitary

Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas

(2015) Jian-Qiang Lu et al.   ENDOCRINE PATHOLOGY

Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas

(2015) Güliz Demirelli Gültekin et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth

(2015) Wenchao Zhou et al.   NATURE CELL BIOLOGY

Management of aggressive pituitary adenomas and pituitary carcinomas

(2014) Anthony Heaney   JOURNAL OF NEURO-ONCOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Clinical significance of macrophage heterogeneity in human malignant tumors

(2013) Yoshihiro Komohara et al.   CANCER SCIENCE

MGMT expression and pituitary tumours: relationship to tumour biology

(2012) Ann McCormack et al.   Pituitary

Endogenous Matrix Metalloproteinases 2 and 9 Regulate Activation of CD4+and CD8+T cells

(2010) Heather L. Benson et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

(2008) Ann I. McCormack et al.   CLINICAL ENDOCRINOLOGY